P53 OVER-EXPRESSION IS AN EARLY EVENT IN THE DEVELOPMENT OF HUMAN SQUAMOUS-CELL CARCINOMA OF THE LARYNX - GENETIC AND PROGNOSTIC IMPLICATIONS

被引:155
作者
DOLCETTI, R
DOGLIONI, C
MAESTRO, R
GASPAROTTO, D
BARZAN, L
PASTORE, A
ROMANELLI, M
BOIOCCHI, M
机构
[1] CTR RIFERIMENTO ONCOL,DIV EXPTL ONCOL 1,VIA PEDEMONTANA OCCIDENTALE 12,I-33081 AVIANO,ITALY
[2] OSPED FELTRE,DIV PATHOL,FELTRE,ITALY
[3] OSPED CIVILE,DIV OTORHINOLARYNGOL,PORDENONE,ITALY
[4] OSPED CIVILE,DIV PATHOL,PORDENONE,ITALY
[5] UNIV FERRARA,DEPT OTORHINOLARYNGOL,I-44100 FERRARA,ITALY
关键词
D O I
10.1002/ijc.2910520204
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tumor-suppressor protein p53 is over-expressed in a large fraction of squamous-cell carcinomas of the larynx (LSCCs). p53 overexpression is dependent upon the synthesis of mutated versions of the protein and has been associated with the malignant progression of certain tumor types. In order to examine the prognostic value of p53 immunodetection in LSCCs, we performed a retrospective analysis on a selected series of tumors, using the PAb 1801 and CMI antibodies. No significant difference in the frequency of p53 over-expression was observed between tumors from patients with early relapse (67%) and those who had been disease-free for more than 5 years (84%). The lack of correlation of p53 immunoreactivity with clinical stage and differentiation grade of LSCCs, together with the coordinated expression of p53 in primary tumors and the corresponding lymph-node metastases, indicate that p53 over-expression is probably unrelated to the biological aggressiveness of these tumors. In addition, the detection of p53 immunostaining in pre-invasive areas as well as in preneoplastic lesions suggests that p53 abnormalities probably constitute a very early event in LSCC development.
引用
收藏
页码:178 / 182
页数:5
相关论文
共 22 条
[1]   ALTERATIONS IN THE P53 GENE AND THE CLONAL EVOLUTION OF THE BLAST CRISIS OF CHRONIC MYELOCYTIC-LEUKEMIA [J].
AHUJA, H ;
BARELI, M ;
ADVANI, SH ;
BENCHIMOL, S ;
CLINE, MJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (17) :6783-6787
[2]  
ALTMANN F, 1952, AMA ARCH OTOLARYNGOL, V56, P121
[3]   CHROMOSOME-17 DELETIONS AND P53 GENE-MUTATIONS IN COLORECTAL CARCINOMAS [J].
BAKER, SJ ;
FEARON, ER ;
NIGRO, JM ;
HAMILTON, SR ;
PREISINGER, AC ;
JESSUP, JM ;
VANTUINEN, P ;
LEDBETTER, DH ;
BARKER, DF ;
NAKAMURA, Y ;
WHITE, R ;
VOGELSTEIN, B .
SCIENCE, 1989, 244 (4901) :217-221
[4]   ISOLATION OF HUMAN-P53-SPECIFIC MONOCLONAL-ANTIBODIES AND THEIR USE IN THE STUDIES OF HUMAN P53 EXPRESSION [J].
BANKS, L ;
MATLASHEWSKI, G ;
CRAWFORD, L .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 159 (03) :529-534
[5]  
BARTEK J, 1991, ONCOGENE, V6, P1699
[6]  
BAUER WC, 1974, CAN J OTOLARYNGOL, V3, P533
[7]   WILD-TYPE P53 CAN INHIBIT ONCOGENE-MEDIATED FOCUS FORMATION [J].
ELIYAHU, D ;
MICHALOVITZ, D ;
ELIYAHU, S ;
PINHASIKIMHI, O ;
OREN, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) :8763-8767
[8]   P53 IN CHRONIC MYELOGENOUS LEUKEMIA IN ACUTE PHASE [J].
FEINSTEIN, E ;
CIMINO, G ;
GALE, RP ;
ALIMENA, G ;
BERTHIER, R ;
KISHI, K ;
GOLDMAN, J ;
ZACCARIA, A ;
BERREBI, A ;
CANAANI, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (14) :6293-6297
[9]   THE P53 PROTO-ONCOGENE CAN ACT AS A SUPPRESSOR OF TRANSFORMATION [J].
FINLAY, CA ;
HINDS, PW ;
LEVINE, AJ .
CELL, 1989, 57 (07) :1083-1093
[10]   P53 MUTATIONS IN HUMAN LYMPHOID MALIGNANCIES - ASSOCIATION WITH BURKITT-LYMPHOMA AND CHRONIC LYMPHOCYTIC-LEUKEMIA [J].
GAIDANO, G ;
BALLERINI, P ;
GONG, JZ ;
INGHIRAMI, G ;
NERI, A ;
NEWCOMB, EW ;
MAGRATH, IT ;
KNOWLES, DM ;
DALLAFAVERA, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (12) :5413-5417